文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

CD7靶向「即用型」CAR-T在复发难治性T细胞恶性肿瘤治疗中展现强劲体内扩增与高疗效

CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
PubMed 文献 · Leukemia · 2023-09-12

GC027是一种「即用型」异基因CD7靶向CAR-T产品,用于T细胞恶性肿瘤。在扩展研究中,12例复发难治性T-ALL患者中11例在输注后1个月内达完全缓解,GC027细胞输注后5-10天达扩增峰值,多数缓解患者4周时流式或qPCR检测不到GC027,1例无进展生存超过3年。

要点

  • 12例复发难治性T-ALL中11例在GC027输注后1个月内达完全缓解。
  • GC027细胞输注后迅速扩增,约5-10天达峰值。
  • 9/11例缓解患者输注4周后流式或qPCR检测不到GC027。

核心结论

  • GC027毒性可控,在复发难治性T细胞恶性肿瘤中展现出优于标准化疗方案的临床疗效。

研究设计与样本

  • 扩展研究纳入12例复发难治性T-ALL患者,评估「即用型」异基因CD7靶向CAR-T产品GC027。

主要发现

  • 12例患者中11例在GC027输注后1个月内T淋巴母细胞快速清除并达完全缓解。
  • GC027细胞自输注起快速扩增,约输注后5-10天达峰值。
  • 11例缓解患者中9例在输注4周后流式细胞术或qPCR检测不到GC027。
  • 1例患者无进展生存超过3年。

临床怎么用

  • 作者认为GC027毒性可控,在复发难治性T细胞恶性肿瘤中临床疗效优于标准化疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell acute lymphoblastic leukemia (T-ALL) represents an area of highly unmet medical needs. Once relapsed, patients have limited treatment options and poor prognosis. T-ALL antigens such as CD7 is extensively expressed in normal T cells and natural killer (NK) cells, and extending the success of CAR-T therapy to T cell malignancies was challenged by CAR-T cell fratricide, high production cost, and potential product contaminations. GC027 is an "off-the-shelf" allogeneic CD7 targeted CAR-T therapeutic product for T cell malignancies. It demonstrated superior cell expansion and antileukemia efficacy in mouse xenograft model. In our previous study, we observed promising efficacy results in the first two relapsed and refractory(R/R) T-ALL patients treated with GC027. In the expanded study, 11 out of 12 patients had rapid eradication of T-lymphoblasts and reached complete response within 1-month after GC027 infusion. GC027 cells expanded quickly beginning at infusion and reached to peak around 5-10 days after infusion. For most patients with a response(9/11), GC027 could not be detected via flow cytometry or qPCR 4 weeks after infusion. One patient had progression free survival of >3 years. With manageable toxicity profile, GC027 demonstrated superior clinical efficacy to standard chemotherapy regimens in (R/R) T cell malignancies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Li S, Wang X, Liu L, et al. CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia. 2023. PMID: 37700087. doi:10.1038/s41375-023-02018-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。